Prime Medicine Q2: positive CGD clinical data, $144M offering, cash runway into 2027

Prime Medicine, Inc.

2025-Q2 EPS reported -$0.81 revenue$2,569,000

First clinical proof-of-concept for Prime Editing: two patients in CGD trial showed restored NADPH oxidase activity above clinical benefit threshold.
Completed $144.2M follow-on offering in August 2025; cash balance pro-forma $259.6M as of June 30, 2025.
Secured up to $24M from Cystic Fibrosis Foundation to advance CF program targeting G542X mutation.
Allan Reine named CEO in May 2025; strategic restructuring and workforce reduction expected to cut cash needs by half through 2027.
Net loss of $52.6M in Q2 2025 (vs. $55.3M in Q2 2024); R&D expenses down to $41.4M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.